

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 28, 2005 (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Yong KWEE
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket Number	053466-0401

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/HS/	A1	PCT	WO 01/77362	A1	Chugai Seiyaku Kabushiki Kaisha	10/18/2001		Abs

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/HS/	A2	CHIRIVA-INTERNATI, Maurizio et al., "Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma", <i>BLOOD</i> , Vol. 100, No. 3, pgs. 961-965, August 1, 2002.	
↓	A3	THURNER, Beatrice et al., "Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma", <i>J. EXP. MED.</i> , Vol. 190, No. 11, pgs. 1669-1678, 1999.	
	A4	SONG, Wenru et al., "Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity", <i>J. EXP. MED.</i> , Vol. 186, No. 8, pgs. 1247-1256, 1997.	
	A5	SPECHT, Jennifer M. et al., "Dendritic Cells Retrovirally Transduced with a Model Antigen Gene are Therapeutically Effective against Established Pulmonary Metastases", <i>J. EXP. MED.</i> , Vol. 186, No. 8, pgs. 1213-1221, 1997.	
	A6	TREON, Steven P., et al., "Immunotherapeutic Strategies for the Treatment of Plasma Cell Malignancies", <i>SEMINARS IN ONCOLOGY</i> , Vol. 27, No. 5, pgs. 598-613, 2000.	
↓	A7	CONDON, Cal et al., "DNA-based immunization by <i>in vivo</i> transfection of dendritic cells", <i>NATURE MEDICINE</i> , Vol. 2, No. 10, pgs. 1122-1128, October 1996.	
/HS/	A8	PORGADOR, Angel et al., "Bone Marrow-generated Dendritic Cells Pulsed with a Class I-restricted Peptide Are Potent Inducers of Cytotoxic T Lymphocytes", <i>J. EXP. MED.</i> , Vol. 182, No. 1, pgs. 255-260, July 1995.	

Examiner Signature	/Hong Sang/ (06/04/2007)	Date Considered	06/04/2007
-----------------------	--------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: April 28, 2005

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known 10/533104

Application Number	Unassigned
Filing Date	Herewith
First Named Inventor	Yong KWEE
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	053466-0401

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/HS/	A9	GONG, Jianlin et al., "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells", <i>NATURE MEDICINE</i> , Vol. 3, No. 5, pgs. 558-561, May 1997.	
/HS/	A10	SZABOLCS, Paul et al., "Retrovirally Transduced Human Dendritic Cells Express a Normal Phenotype and Potent T-Cell Stimulatory Capacity", <i>BLOOD</i> , Vol. 90, No. 6, pgs. 2160-2167, September 1997.	
/HS/	A11	SYRENGELAS, Anthanasia D. et al., "DNA immunization induces protective immunity against B-cell lymphoma", <i>NATURE MEDICINE</i> , Vol. 2, No. 9, pgs. 1038-1041, September 1996.	

Examiner
Signature

/Hong Sang/ (06/04/2007)

Date
Considered

06/04/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUN 23 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: June 23, 2006

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/533,104
Filing Date	04/28/2005
First Named Inventor	Yong KWEE
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	053466-0401

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/HS/	B1	EP	1 059 533	A1	Chugai Seiyaku Kabushiki Kaisha	12/13/2000		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/HS/	B2	HUNDEMER et al., "Identification of T Cell Epitopes within the Plasmacell Antigen HM1.24", 2002, Blood, Vol. 100, No. 11, pg. Abstract No. 5088, XP009063835.	
	B3	NICOLA DI et al., "Gene Transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors", 1998, Cancer Gene Therapy, Vol. 5, No. 6, pgs. 350-356.	
	B4	OHTOMO et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells", Biochemical and Biophysical Research Communications, 1999, Vol. 258, No. 3, pgs. 583-591.	
	B5	OZAKI et al., "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That is Enhanced by Cytokine Stimulation of Effector Cells", Blood, 1999, Vol. 93, No. 11, pgs. 3922-3930.	
/HS/	B6	REW, et al, "Potent anti-tumour cytotoxic T lymphocytes directed against the myeloma antigen HM1.24", Blood, 2003, Vol. 102, No. 11, pg. 112A, XP009063769.	

Examiner Signature

/Hong Sang/ (06/04/2007)

Date Considered

06/04/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

VASH_1634298.1